Moneycontrol PRO

At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

Jump to
  • Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 5.1 percent Y-o-Y (up 1.3 percent Q-o-Q) to Rs. 6,555.2 crore, according to Prabhudas Lilladher.

  • Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 5.1 percent Y-o-Y (up 1.3 percent Q-o-Q) to Rs. 6,555.2 crore, according to Prabhudas Lilladher.

  • Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct

  • Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher

  • Aurobindo Pharma Q4 PAT may dip 26.6% YoY to Rs 588.1 cr: Prabhudas Lilladher

  • Aurobindo Pharma Q3 PAT may dip 73% YoY to Rs 795.3 cr: Prabhudas Lilladher

  • Aurobindo Pharma Q2 PAT may dip 17.3% YoY to Rs 666.3 cr: Prabhudas Lilladher

  • Aurobindo Pharma Q1 PAT seen up 1.3% YoY to Rs 791.1 cr: KRChoksey

  • Aurobindo Q1 PAT may dip 1.7% YoY to Rs 767.6 cr: ICICI Direct

  • Aurobindo Q4 PAT seen up 6% YoY to Rs. 901 cr: Sharekhan

  • Aurobindo Pharma Q3 PAT seen up 17.2% YoY to Rs. 719 cr: Prabhudas Lilladher

  • Aurobindo Pharma Q4 profit may report double-digit growth led by key geographies

  • Aurobindo Q2 PAT seen up 6% YoY to Rs. 675.1 cr: Emkay

  • Aurobindo Pharma Q4 PAT seen up 17.8% YoY to Rs. 641.6 cr: Kotak

  • Aurobindo Pharma Q4 PAT seen up 18.2% YoY to Rs. 624.9 cr: Prabhudas Lilladher

  • Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings

  • Aurobindo Pharma Q3 preview: Profit may get a boost; outlook on US business key

  • Aurobindo Q3 PAT seen up 11.5% YoY to Rs. 729 cr: Sharekhan

  • Aurobindo Pharma Q3 PAT seen up 13.8% YoY to Rs. 669.1 cr: ICICI Direct

  • Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila

  • Q2 preview: Muted US business growth likely to hit Aurobindo Pharma's performance

  • Aurobindo Pharma Q2 PAT may dip 28.3% YoY to Rs. 560 cr: HDFC Securities

  • Aurobindo Q2 PAT may dip 23.1% YoY to Rs. 600 cr: Sharekhan

  • Aurobindo Pharma Q2 PAT may dip 23% YoY to Rs. 601.9 cr: ICICI Direct

  • Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347